Readthrough of stop codons by use of aminoglycosides in cells from xeroderma pigmentosum group C patients

Experimental Dermatology

Volumn 24, Issue 4, 2015, Pages 296-297

  Kuschal, Christiane ^a   Khan, Sikandar G ^a   Enk, Benedikt ^a   Digiovanna, John J ^a   Kraemer, Kenneth H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Aminoglycosides; DNA repair; Premature termination codons; Skin cancer; Xeroderma pigmentosum

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC G 418; KANAMYCIN; MESSENGER RNA; NEOMYCIN; PAROMOMYCIN; XERODERMA PIGMENTOSUM GROUP C PROTEIN; DNA BINDING PROTEIN; GENTAMICIN; MUTANT PROTEIN; STOP CODON; XPC PROTEIN, HUMAN;

DRUG EFFECT; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; LETTER; PROTEIN EXPRESSION; STOP CODON; SYSTEMIC THERAPY; TOPICAL TREATMENT; XERODERMA PIGMENTOSUM; XPC GENE; CELL CULTURE; DRUG EFFECTS; GENETICS; METABOLISM; PERSONALIZED MEDICINE; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; AMINOGLYCOSIDES; CELLS, CULTURED; CODON, NONSENSE; DNA-BINDING PROTEINS; GENE EXPRESSION; GENTAMICINS; HUMANS; MUTANT PROTEINS; PRECISION MEDICINE; RNA, MESSENGER; XERODERMA PIGMENTOSUM;

EID: 84925946828     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/exd.12655     Document Type: Letter

References (9)

1. DiGiovanna J J, Kraemer K H. J Invest Dermatol 2012: 132: 785-796.
2. Kuschal C, DiGiovanna J J, Khan S G et al. Proc Natl Acad Sci USA 2013: 110: 19483-19488.
3. Lee H L, Dougherty J P. Pharmacol Ther 2012: 136: 227-266.
4. Kellermayer R, Szigeti R, Keeling K M et al. J Invest Dermatol 2006: 126: 229-231.
5. Cogan J, Weinstein J, Wang X et al. Mol Ther 2014: 22: 1741-1752.
6. Khan S G, Metin A, Gozukara E et al. Hum Mol Genet 2004: 13: 343-352.
7. Popp M W, Maquat L E. Mol Cells 2014: 37: 1-8.
8. Khan S G, Yamanegi K, Zheng Z M et al. Hum Mutat 2010: 31: 167-175.
9. Keeling K M, Wang D, Dai Y et al. PLoS One 2013: 8: e60478.